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Background. In combination with everolimus (EVL), cyclosporine A (CsA) may be used at low exposure, so reducing
the risk of renal dysfunction in renal transplant recipients (RTR). We evaluated whether higher exposure of EVL could
allow a further reduction of CsA.
Methods.De novo RTR were randomized to standard exposure EVL (C0 3–8 ng/mL) with low-concentration CsA (C2 mainte-
nance levels 350–500 ng/mL, group A) or higher EVL exposure (C0 8–12 ng/mL) with very low-concentration CsA (C2 mainte-
nancelevels150–300ng/mL,groupB).Theprimaryendpointswere6-monthcreatinineclearance(CrCl)andbiopsy-provenacute
rejection (BPAR) rate. After 6 months, patients were followed up (observational extension) to 12 months.
Results. Two hundred eighty-five RTR (97% from deceased donors) were enrolled. Two patients per group died
(1.4%). The 6-month death-censored graft survival was 90.2% in group A and 97.9% in group B and was unchanged at
12 months (P0.007). There was no significant difference between groups at 6 months in CrCl (59.9 vs. 57.8 mL/min)
and BPAR rates (14.7% vs. 11.9%) and also at 12 months (CrCl 62.520.7 vs. 61.322.0 mL/min, BPAR 14.7% vs.
14.1%). No significant differences were seen in treated acute rejections, steroid-resistant acute rejections, treatment
failures, or delayed graft function, although there was a trend to better results in group B.
Conclusions.EVLgivenathigherexposurefor6monthsplusvery lowCsAconcentrationmayobtainlowacuterejectionrateand
good graft survival in De novo renal transplantation. However, there was no difference between groups in CrCl.
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Everolimus is a macrolide lactone with proliferationsignal inhibitor activity. Because of the introduction of
a 2-hydroxyethil group in position 40 (1), it differentiates
from sirolimus for a shorter half-life. In a randomized con-
trolled trial (RCT), everolimus (EVL) was not inferior to my-
cophenolate mofetil in preventing acute rejection (AR) when
both drugs were given in combination with standard doses of
cyclosporine A (CsA) (2). However, the mean creatinineThis work was supported by Novartis Farma SpA, Italy.
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clearance (CrCl) levels were lower in patients assigned to EVL
when compared with those assigned to mycophenolate
mofetil. Further studies showed that the risk of AR was related
to low EVL blood levels rather than to CsA blood levels (3),
suggesting that CsA dose could be reduced, when given in asso-
ciation with EVL, without compromising efficacy. In another
RCT, renal transplant recipients given basiliximab, corticoste-
roids, and EVL (3 mg/day) were assigned to reduced-dose CsA
(C0 levels between 50 and 100 ng/mL) or standard dose CsA (C0
levels between 150 and 250 ng/mL). After 3 years, the efficacy
failure (AR, graft loss, death, and lost to follow-up) was sig-
nificantly lower in patients receiving reduced-dose CsA (4).
Two other multicenter trials confirmed excellent 1-year graft
survival and good renal function in renal transplant patients
assigned to receive 1.5 or 3 mg/day of EVL in combination
with reduced-dose CsA (5).
This RCT evaluated possible differences on safety and
efficacy between two regimens based on the EVL-CsA associ-
ation. De novo renal transplant recipients were randomized
to receive EVL at a dose targeted to maintain blood levels (C0)
between 3 and 8 ng/mL and reduced-dose CsA or to receive
higher doses of EVL (C0 8 –12 ng/mL) in combination with
very low CsA doses.
MATERIALS ANDMETHODS
Study Design and Patient Population
This 6-month, prospective, open-label parallel group
RCT with 12-month follow-up enrolled recipients (18 to 65
years) of single kidney transplant from a deceased or non-
human leukocyte antigen (HLA) identical living donor, aged
14 to 65 years. The study protocol was approved by ethical
committees at each participating institution. The study was
conducted in compliance with the provisions of the Declara-
tion of Helsinki and Good Clinical Practice guidelines, and all
patients gave informed consent in written form to study par-
ticipation. Exclusion criteria were pregnancy, a current panel
reactive antibody titer more than or equal to 50%, a previous
transplant failed within 1 year, diagnosis of focal segmental
glomerulosclerosis or primary hyperoxaluria, chronic active
hepatitis, HIV positivity, plasma cholesterol levels more than
or equal to 350 mg/dL (9.1 mmol/dL), or triglyceride levels
500 mg/dL (5.6 mmol/L).
Within 24 hr from graft reperfusion, patients were ran-
domized 1:1 to the following groups:
Group A: Standard EVLLow-Exposure Neoral
The starting dose of EVL (Novartis Ag, Basel, Switzer-
land) was 0.75 mg twice daily (b.i.d.), then adjusted to reach
and maintain a blood level of 3 to 8 ng/mL until the end of
month 6. The initial dose of Neoral (CsA for microemulsion;
Novartis Ag, Basel, Switzerland) was 2 mg/kg b.i.d., adjusted
to reach a target blood level (C2) of 500 to 700 ng/mL within
day 5 and to maintain the same level until the end of month 2,
then slowly reduced to reach 350 to 500 ng/mL within month
6. Suggested C2 levels until month 12 were 350 to 450 ng/mL.
Group B: Upper EVLVery Low-Exposure Neoral
Upper target EVLvery low-exposure Neoral. As in
group A, EVL was started at 0.75 mg b.i.d, and the dose ad-
justed to reach a blood level of 3 to 8 ng/mL in the first week.
After the first week, the EVL dose was adjusted to reach a C0
of 8 to 12 ng/mL. Neoral starting dose was 2 mg/kg b.i.d., then
adjusted to target a C2 level of 500 to 700 ng/mL within day 5
and until day 7; after day 8, when the EVL target levels had
been reached, the CsA dose was reduced to target a C2 of 250
to 450 ng/mL by the end of month 2, then tapered to 200 to
400 by the end of month 4 and 150 to 300 ng/mL by the end of
month 6. The same blood level had to be maintained until
month 12.
EVL blood levels were monitored at local laboratory using
the fluorescence polarization immunoassay kit (Innofluor Cer-
tican, Seradyn). All patients received basiliximab (Simulect; No-
vartis Ag, Basel, Switzerland) 20 mg intravenously on days 0 and
4 after transplantation, intravenous methylprednisolone (500
mg on day 0 and 40 mg on day 1), and oral prednisone (20
mg/day) in a single morning dose until day 7, then gradually
tapered to a dose of 5 mg/day after day 45.
Randomization codes were generated at Novartis Farma
SpA (Origgio, Varese, Italy), using a validated computer
method. Each center was assigned an adequate number of
sealed envelops, each of them labeled with a unique patient
number, that were opened after transplantation immediately
before the administration of the first EVL dose.
The core study lasted 6 months. Patients completing
the core study were entered in an observational follow-up and
allowed to continue the assigned treatment.
ARs were treated with intravenous methylprednisolone
pulses; anti-lymphocyte antibodies were allowed for grade III
rejections or steroid-resistant rejections (see definitions). Cy-
tomegalovirus (CMV) prophylaxis was mandatory in CMV-
negative recipients with CMV-positive donors. All patients
received prophylactic treatment for Pneumocystis carinii
pneumonia for 6 months.
Study Assessments
Efficacy
The primary outcome measures were the 6-month
CrCl estimated according Cockcroft and Gault (6) and the
proportion of patients with biopsy-proven acute rejection
(BPAR) in either arm. The graft biopsies were examined lo-
cally according to the Banff ’97 criteria (7).
Secondary outcome measures were the proportion of
patients with graft loss, death, treated ARs, antibody-treated
AR, and the estimated glomerular filtration rate (GFR) ac-
cording to Nankivell (8). The presence and duration of de-
layed graft function (DGF), defined as a need for dialysis in
the postoperative period, were also recorded.
Risk of BPAR and Blood Levels of Drugs
The correlation of the EVL and CsA blood levels with
the presence of BPAR within the first 3 months after trans-
plantation was investigated. To estimate the effect of the con-
centration of the drugs on the risk of BPAR, a survival analysis
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of EVL and CsA blood levels combinations using a Hazard
model with time-dependent covariates was performed (9).
Safety
All adverse events (AEs), serious AEs (SAEs), and all
concomitant medications were recorded during the study.
Hematology and serum creatinine were checked weekly in the
first month and then monthly. Vital signs and biochemistry
examinations were recorded at 1, 3, 6, and 12 months after
transplantation.
Hypercholesterolemia was defined as a cholesterol value
more than or equal to 250 mg/dL (6.41 mmol/L) and hypertri-
glyceridemia as a triglyceride value more than or equal to 250
mg/dL (2.80 mmol/L). New onset diabetes after transplantation
was defined as a fasting serum glucose level more than 126
mg/dL and administration of insulin or oral hypoglycemic drugs
in patients without diabetes at transplantation.
Statistical Methods
Assuming a common SD of 17 mL/min for CrCl, 140
patients per group were required to have 80% power of de-
tecting a 6-month difference between groups of 6 mL/min, in
favor of group B, at a 0.05 level of significance for a two-tailed
test. To assess whether group B was not inferior to group A for
prevention of BPAR, we hypothesized a 6-month rate of
BPAR in group A of 10% to 15%, according to a previous trial
(5). The limit of noninferiority, that is, the maximum group
B-group A difference, was set to 15%. For a 0.975 one-sided
confidence interval, with a sample size of 140 patients per
arm, the power associated with a BPAR rate in group A of
10% to 15% was always higher than 90%.
In the main analysis of CrCl, when the 6-month value
was missing, the last observed value was carried forward (Last
Observation Carried Foward [LOCF] method) (10), unless
the patient lost the graft or died, in which case a CrCl value of
“0” was imputed. A nonparametric test (Wilcoxon-Mann-
Whitney) was used.
All secondary efficacy analyses were run on the Inten-
tion To Treat (ITT) population. The time to the first biopsy-
proven, treated or antibody-treated AR and the time to graft
loss or death were analyzed by the product limit method
(Kaplan-Meier). The survival curves were compared by log-
rank test.
Post Hoc Analysis
A post hoc analysis was conducted on the treatment
compliant population, defined as patients in whom at least
50% of both CsA and EVL levels from month 2 were within
the target blood levels in each group. This analysis was con-
ducted both on the CrCl (using a LOCF) and on the GFR in
patients with functioning graft.
RESULTS
Patient Characteristics and Demographics
Between May 2005 and January 2007, 285 patients were
enrolled into the study before transplant surgery in 20 centers
in Italy. None of the eligible patients was excluded from ran-
domization and subsequent analysis. Only eight patients
(2.8%) received a kidney from a living donor. Patient dispo-
sition is shown in Figure 1. There were no differences between
the two groups in the main donor or recipient demographic
characteristics (Table 1).
Efficacy
Primary Endpoints
The mean 6-month CrCl in patients with functioning
grafts was 59.918.6 mL/min in group A and 57.819.3 mL/
min in group B. The difference between groups was not sig-
nificant, even when the LOCF approach was used (P0.7). At
12 months, the mean CrCl was 62.520.7 mL/min in group A
versus 61.322.0 mL/min in group B. In this group, the re-
covery of CrCl after transplantation tended to be faster, al-
though the differences with group A were never significant at
any time point. The mean GFR values (Nankivell) at 6 and 12
months were, respectively, 62.315.6 and 64.817.7 mL/
min in group A in comparison with 60.016.4 and
63.818.3 mL/min in group B. (PNS, Fig. 2).
Within month 6, the BPAR event rate was 14.0% (20/
143) in group A and 11.3% (16/142) in group B. The upper
limit of the 97.5% confidence interval of the difference was
4.99% (i.e.,15%), confirming the noninferiority of group B
versus group A. Kaplan Meier estimates of BPAR at 6 months
are reported in Table 2. Between 6 and 12 months, another
patient in group A and four in group B developed a BPAR
(PNS). The cumulative probability of BPAR at 1 year in
groups A and B was, respectively, 14.7% and 14.1%.
FIGURE 1. Patient disposition.
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Post Hoc Analysis
The treatment compliant population comprised 107
patients in group A and 57 patients in group B. The 6-month
mean values of CrCl, using the LOCF approach were, respec-
tively, 52.926.2 and 58.523.2 mL/min in groups A and B,
with a difference between groups of 5.5 mL/min in favor of
group B (PNS). In the treatment compliant population, the
probability of having a BPAR within the first 6 months were
14.9% in group A and 12.6% in group B (PNS).
Secondary Endpoints
Treated AR (either confirmed or not by graft biopsy)
occurred in 29 patients (20.3%) of group A and in 23 patients
of group B (16.2%; PNS) in the first 6 months and in one
further patient of group A versus 6 patients of group B
(P0.06) after month 6. The cumulative number of patients
with rejection within month 12 was 30 (21%) in group A and
29 (20.4%) in group B. Steroid resistant AR occurred in nine
patients of group A (6.3%) and in three of group B (2.1%;
P0.08). There was a trend for less severe BPAR in group B:
in fact, there were 11 episodes of grade II to III BPAR in group
A as opposed to four in group B (P0.065, NS). Table 2
reports the 6-month estimates (Kaplan and Meier) of having
a treated acute rejection or a steroid resistant acute rejection
in the two groups. Ten patients of group A received a second
transplant: two lost their allograft and two had a reversible,
steroid-resistant AR. None of the five patients of group B who
received a second transplant, lost their allograft, or had a ste-
roid resistant AR. Of the seven group A patients with 20% to
50% anti-HLA antibodies, two lost their allograft and two had
a reversible, steroid resistant AR. In group B, of the six pa-
tients with preformed anti-HLA antibodies, one lost the graft
because of rejection and another patient had a reversible, steroid
resistant AR. Overall, 22 study patients (7.8%) had one or more
immunological risk factors. In this subgroup there were 4 graft
losses (18.2%); in the remaining patients without immunologi-
cal risks, the overall graft loss rate was 5.0% (13/258).
DGF occurred in 44 patients (30.8%) in group A and 33
(23.2%) in group B (PNS). Excluding four patients in
group A who received nonviable kidneys, the mean post-
FIGURE 2. Creatinine clearance. Mean (SE) creatinine
clearance, calculated according Cockcroft and Gault for-
mula, in patients with functioning grafts. Open square:
group A (standard everolimus). Black diamonds: group B
(upper everolimus). There were no significant differences.
TABLE 1. Baseline characteristics of study population
Standard
everolimus,
group A
(N143)
Upper
everolimus,
group B
(N142)
Age (yr)
Mean (SD) 45.8 (10.6) 45.4 (11.7)
Range 22–66 19–65
Male sex (%) 65.7 62.7
Previous transplant (%) 10 (7.0) 5 (3.5)
Hypertension at transplantation (%) 116 (81.1) 126 (88.7)
Disease leading to TX (%)
Glomerulonephritis 56 (39.2) 38 (26.8)
Interstitial nephritis/pyelonephritis 11 (7.7) 13 (9.2)
Polycystic kidney disease 26 (18.2) 23 (16.2)
Nephrosclerosis 8 (5.6) 20 (14.1)
Urinary obstruction/vesicoureteral
reflux
3 (2.1) 9 (6.3)
Other/unknown 39 (27.3) 39 (27.5)
Donor age, yr (SD) 44.6 (13.0) 43.8 (13.9)
Donor sex (M/F) 83/60 74/68
Living donor 3 (2.1) 4 (2.8)
% Mean PRA (SD) 2.1 (7.2) 1.6 (6.5)
Mean HLA incompatibilities (SD) 3.5 (1.2) 3.4 (1.2)
Cold ischemia time, hr (SD) 14.5 (4.7) 13.8 (4.9)
Recipient CMV/Donor
CMV (%)
12 (8.4) 11 (7.7)
TX, transplantation; HLA, human leukocyte antigen; CMV, cytomegalovirus.
TABLE 2. Primary and secondary efficacy measures
at 6 mo
Standard
everolimus,
group A
(N143)
Upper
everolimus,
group B
(N142)
Overall
(N285)
Patient survivala 98.6 98.6 98.6
Graft survival
(death censored)a
90.2 97.9b 94.1
Graft survival
(not death censored)a
88.8 96.5b 92.6
BPARa 14.7 11.9 13.3
Treated acute rejection/
BPARc
20.6 16.4 17.5
Steroid resistant acute
rejectiond
6.3 2.1 4.2
a Probability of event.
b P0.05.
c Treated ARs were defined as a serum creatinine increase30% over the
baseline, in absence of renal biopsy, not explained by other medical or sur-
gical complications, that improved after administration of MPP.
d Actual proportion of patients with steroid-resistant AR. AR was classi-
fied as steroid-resistant when serum creatinine levels did not improve 4 to 5 d
after the administration of intravenous MPP. Any suspected rejection was
carefully investigated to exclude vascular occlusion, urinary obstruction, or
laboratory errors in serum creatinine determination. Severity of acute rejec-
tion is reported according Banff criteria ’97.
BPAR, biopsy-proven acute rejection; AR, acute rejection; MPP, meth-
ylprednisolone pulses.
© 2009 Lippincott Williams & Wilkins 1197Salvadori et al.
transplant time on dialysis was 9.313.1 days (1 to 68) in
group A and 7.27.3 days (1 to 27) in group B (P0.4, NS).
The mean serum creatinine values at 6 and 12 months
were, respectively, 1.560.52 and 1.510.55 mg/dL in group
A and 1.630.59 and 1.550.62 in group B (PNS).
Graft Loss and Deaths
In group A, graft never recovered any function in four
patients (2.9%). Ten other patients (7%) lost their graft, two
because of renal thrombosis after recovery of graft function,
two because of irreversible rejection, and one because of kid-
ney rupture; four other patients had an AR superimposed to
DGF and one was nephrectomized because of a donor-derived
mycotic aneurysm. Three patients (2.1%) lost their graft in
group B, respectively, because of renal vein thrombosis, renal
infarction, and kidney rupture/DGF. No graft failure occurred
after the sixth month.
Two patients died (1.4%) in group A, one of myocar-
dial infarction and one of pulmonary edema. Two patients
died (1.4%) in group B, respectively, from myocardial infarc-
tion and ruptured arterial mycotic aneurysm of donor origin.
All deaths occurred within the sixth month.
According to ITT analysis, the 6- and 12-month death-
censored graft survival was 90.2% in group A and 97.9% in
group B (P0.007). Excluding the four patients who received
a nonviable kidney, the 6-month death-censored graft sur-
vival in group A was 92.8%.
Immunosuppression
The mean EVL dosage was 1.440.6 mg/day in
group A and 2.231.0 mg/day in group B at 6 months; it
was 1.450.6 and 2.311.0 mg/day at 12 months. The
blood levels of EVL tended to remain toward the higher limit
of the scheduled range in group A and toward the lower limit in
group B (Fig. 3).
The mean dosage of CsA at 6 months was 1.920.5
mg/kg per day in group A versus 1.560.6 mg/kg per day in
group B; at 12 months, the mean dosages in groups A and B
were, respectively, 1.740.5 and 1.430.6 mg/kg per day.
The mean CsA C2 levels were within the scheduled range in
group A but exceeded the upper target limit in group B, being
405.7209 and 332.7152 ng/mL at 6 and 12 months, re-
spectively (Fig. 3).
The mean prednisone daily dosages were 7.324.8 mg
in group A and 6.23.2 mg in group B at 6 months and
5.091.8 and 5.54.5, respectively, at 12-month (PNS).
Center Effect
A post hoc analysis showed that the graft loss rate by
center ranged from 0% to 18.2%, and it was 8.16% (8/98
patients) in centers including less than 14 patients in the
study, as compared with 4.8% (9/187 patients) in centers in-
cluding 14 patients or more. There were no significant differ-
ences between centers about the rate of BPAR or mean CrCl.
Safety
There were no differences between groups in the per-
centage of patients who experienced at least one AE, one SAEs
or in the number of patients who discontinued study treat-
ment due to AE (Tables 3–5). Although frequently reported
as an AE, anemia was mainly found in the early posttransplant
period and was reported as SAE in only 2.8% of the patients in
group A and 2.1% in group B. Mean hemoglobin levels at 6
months were 12.61.5 g/dL in group A versus 12.51.9 g/dL
in group B and tended to improve up to the twelfth month
(13.01.5 vs. 12.81.6 g/dL), respectively. However, 23 pa-
tients (16.1%) in group A and 33 (23.2%) in group B were
given erythropoietin as a maintenance therapy (PNS). Ar-
thralgia and hypocalcemia were more frequent in group B,
Urinary tract infections, dyslipidemia, pyrexia, peripheral
edema, and lymphocele were other frequently reported AEs,
without significant differences between groups. New onset
diabetes after transplantation was diagnosed in 2.1% of pa-
tients in group A and 4.9% in group B (NS). Two patients in
group B (1.4%) and one patient in group A (0.7%) developed
nonmelanoma skin cancer. Infection was the most frequently
reported SAE, followed by pyrexia (more frequent in group
A) and lymphocele (more frequent in group B).
Overall, approximately 17% of enrolled patients
stopped EVL treatment within month 6 due to AEs, mostly
because of early events (nonimmunologic graft complica-
tions in group A [4.9%] and graft dysfunction in group B
[2.8%]). After the sixth month, no patient in group A versus
6 in group B (P0.05) had to interrupt EVL due to AEs (in-
creased serum creatinine 2, anemia 1, edema 1, mucositis
1, proteinuria 1). One patient in group A (gum hyperpla-
FIGURE 3. Mean blood levels of immuno-
suppressive drugs. Group A (standard everoli-
mus,open squares); groupB (upper everolimus,
black diamonds). Vertical bars represent the in-
terquartile ranges (25%–75%).
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sia) and three patients in group B (abdominal abscess, pan-
creatitis, and urinary tract infection, respectively) also
changed immunosuppression. Table 5 reports the AEs re-
quiring study drug discontinuation within month 12.
Infections
The overall incidence of serious infections (requiring
hospitalization) was low and similar in the two groups (10.5%
in group A and 14.5% in group B, Table 4).
Blood Pressure
Before transplantation, 81.1% of patients in group A
and 88.7% in group B were on antihypertensive treatments,
that were maintained almost unchanged after transplanta-
tion. There was no difference between groups A and B in the
mean number of antihypertensive medication assumed dur-
ing study (2.6 vs. 2.8). In both groups, systolic blood pressure
at 6 months was significantly decreased in comparison with
pretransplant values (from 13621 to 13115 mm Hg in
group A, from 14021 to 13417 mm Hg in group B,
P0.05 for both). Diastolic blood pressure was 79.19.0 mm
Hg in group A and 80.19.1 mm Hg in group B at 6 months
The mean levels of blood pressure at 12 months were 13116
mm Hg or 799.4 mm Hg in group A versus 13418 mm Hg
and 8111 mm Hg in group B.
Laboratory Examination
Mean plasma cholesterol levels at transplantation
were 17150 mg/dL in group A and 16943 in group B.
Cholesterol mean values were 234.948 mg/dL in both
groups at 6 months and 231.440.1 versus 234.445.9
mg/dL at 12 months. Triglycerides levels at transplantation
were 154.598 versus 149.595 mg/dL in groups A and B,
220.4118 versus 236.0131 mg/dL at 6 months, and
195.493 versus 224.0115 mg/dL at 12 months. Statins
were administered in 45.1% and 60.6% of patients in
groups A and B, respectively.
There were only small changes in the mean values of
leukocytes and platelets during study (data not shown).
Drug Blood Levels/BPAR Relationship
Most ARs occurred within the first 3 months after trans-
plantation. The mean C0 EVL and C2 CsA blood levels at day 7,
month 1, and month 3 were, respectively, 6.1, 8.1, and 8.2 ng/mL
and 734, 631, and 511 ng/mL. Overall, the incidence of BPAR in
TABLE 3. Adverse events within 12 mo: listing of more
frequent adverse events by system organ class and
preferred term
Adverse events (%)
Standard
everolimus,
group A
(N143)
Upper
everolimus,
group B
(N142)
Blood and lymphatic disorders 51.8 59.9
Anemia 48.3 56.3
Infections and infestations 67.1 62.0
Urinary tract infection 53.9 45.1
Metabolism and nutrition disorder 86.1 91.6
Dyslipidemia 36.4 45.1
Hyperuricemia 19.6 19.1
Hypocalcemiaa 13.3 23.2
Hypercholesterolemia 14.7 15.5
Hypokalemia 19.6 15.5
General disorders 51.1 48.6
Pyrexia 30.1 26.1
Peripheral edema 22.4 23.2
Musculoskeletal and connective
tissue disorders
15.4 16.2
Arthralgiaa 2.8 8.5
Vascular disorders 42.0 45.8
Hypertension 19.6 21.1
Lymphocele 15.4 21.1
Transplant complications 25.2 16.2
Renal dysfunction 11.2 17.6
Gastrointestinal disorders 34.3 40.1
Diarrhea 11.2 9.9
Constipation 7.7 12.7
New onset diabetes 2.1 4.9
a Hypocalcemia (P0.05) and arthralgia (P0.05) were more frequently
observed in group B.
TABLE 4. Adverse events within 12 mo: listing of
serious adverse events and cancer
Serious adverse events (%)
Standard
everolimus,
group A
(N143)
Upper
everolimus,
group B
(N142)
Any event 52.5 50.1
Blood and lymphatic disorders 4.9 2.8
Anemia 3.5 2.1
Cardiac disorders 2.8 4.9
Infections and infestations 10.5 14.1
Urinary tract infection 1.4 3.5
CMV infection 1.4 2.1
Pneumonia 1.4 2.1
Metabolism and nutrition disorder 0.7 2.1
Diabetes — 0.7
General disorders 11.2 7.8
Pyrexia 9.1 7.0
Respiratory disorders 4.9 2.1
Pneumonitis 3.5 1.4
Vascular disorders 9.8 14.1
Aneurism 2.8 0
Deep vein thrombosis 1.4 2.8
Lymphocele 3.5 8.5
Renal and urinary disorders 14.0 9.9
Renal impairment 2.1 1.4
Ureteric stenosis 3.5 1.4
Gastrointestinal disorders 4.9 7.8
Cancer 1.4 1.4
Basal cell carcinoma 0 1.4
Epithelioma 0.7 0
Neoplasm, unspecified 0.7 0
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the first 3 months was 0.11 (Kaplan and Meier). The risk of
BPAR in the first 3 months after transplantation was significantly
correlated with the presence of low EVL C0 levels (P0.05) but
not with CsA C2 levels (P0.131, NS).
DISCUSSION
A major challenge in renal transplantation is the avoid-
ance of calcineurin inhibitors (CNIs). A few controlled trials
evaluated the use of CNI-free regimens (11–14), but in-
creased rates of AEs (13) or rejection (14) were reported.
Some investigators warned that CNI should not be aban-
doned (15, 16), but there is no doubt that a minimization in
their dosage is desirable to reduce the CNI-related morbidity.
In this regard, the synergistic interaction between CsA and
EVL can provide the rationale to reduce the doses of CsA (17).
The efficacy of EVL combined with low doses of CsA in renal
transplantation has been confirmed (4, 5), but the optimal
dosage of CsA and EVL when given in combination is still
unknown. Aim of this trial was to elucidate whether there was
a difference between a regimen based on the association of
low-dose CsA with standard exposure to EVL or a regimen
based on even lower doses of CsA combined with higher ex-
posure to EVL.
The cumulative mortality was low (1.4%) and was
mainly caused by cardiac events that occurred in patients with
preexisting risk factors. The graft survival was significantly
better in group B, with only three failures, than in group A (14
graft losses). Vascular thrombosis or kidney rupture was the
cause of graft loss in 6 of 281 patients (2.1%), a rate compat-
ible with the 2% to 7% reported in adult renal transplant (18).
The cumulative graft survival censored for death, including
the four patients who received a graft that never functioned
(94.1%), was similar to the graft survival (91.9 –96.4) re-
ported in RCT recently published (14, 19), despite the rele-
vant number of patients with immunological risk factors
(7.8%) and the high proportion of deceased donors (97%) in
our series.
It is interesting to note that in our study, the rate of
graft loss seemed to be larger in centers that included a
lower number of patients. This is in agreement with the
observation that centers with low volume kidney trans-
plants reports a higher incidence of graft loss when com-
pared with high volume centers (20).
The noninferiority in the BPAR rate of group B versus
group A was achieved. However, no difference was seen in the
primary outcome measure, namely CrCl. At 6 and 12 months,
the mean CrCl was similar in the two groups, ranging around
60 mL/min. In the treatment compliant population, a differ-
ence of 5 mL/min in CrCl was observed in favor of group B,
but this difference was not significant, possibly because of the
reduced number of patients in this analysis. In group A, a
higher number of patients showed DGF, and the median du-
ration of DGF was longer, but the differences with group B
were not significant.
As expected, the cumulative proportion of treated AR
within 6 months (17.5%) was higher than that of BPAR
(13.3%). This difference of 4.2%is comparable with differ-
ences ranging from 4.5% to 6% observed in other multicenter
RCT (14, 19, 21). No significant difference was seen in the
incidence of treated or steroid-resistant AR between groups.
However, there were more grade II or III rejections in group A
and more patients in group A proved to be steroid resistant
and had to be treated with antilymphocyte antibodies. No
patient in group B lost the graft with a concomitant diagnosis
of AR in comparison with six in group A (P0.05).
Anemia was frequently reported, mainly in the first period
after transplant, but the mean levels of hemoglobin approached
the normal values at 6 and 12 months after transplantation, al-
though approximately 20% of the patients of either group was
given erythropoietin. Anemia was reported as serious in less
than 3% of patients in both groups. Treatment with EVL may
be associated with hyperlipemia and myelosuppression (2, 4,
5). Also in our study, cholesterol and triglyceride levels were
increased, although the mean values were at borderline levels
according to National Cholesterol Education Program
Guidelines (22). However, approximately 80% of the patients
took serum lipids modifying agents, mainly statins. The over-
all incidence of De novo hyperglycemia or diabetes was com-
TABLE 5. Adverse events causing study/study drug
discontinuation (%) within 12 mo
Standard
everolimus,
group A
(N143)
Upper
everolimus,
group B
(N142)
Any event 17.5 23.2
Anemia 0.7 0.7
Hemolytic uremic syndrome 0.7 0
Leukopenia 2.1 1.4
Thrombocytopenia 0.7 1.4
Acute myocardial infarction 0.7 0.7
Cardiac arrest 0 0.7
Cardiomyopathy 0.7 0
Apthous stomatitis 0 2.1
Mucositis 0 0.7
Gingival hyperplasia 0.7 0
Pancreatitis 0 0.7
Peripheral edema 0.7 1.4
Kidney transplant rejection 5.6 4.2
Abdominal abscess 0 0.7
CMV infection 0.7 0
Urinary tract infection 0 0.7
Non immunological graft
complications
4.9 1.4
Increased serum creatinine 0.7 2.8
Arthralgia 0 2.8
Arthropathy 0 0.7
Osteonecrosis 0 0.7
Tremor 0 0.7
Renal impairment 0 1.4
Pneumonitis 0 0.7
Pulmonary edema 0.7 0
Aneurysm 0.7 0
Deep vein thrombosis 0 0.7
Adverse events (percentage of patients with AE) are listed independently
from the relationship with study drug, including SAE, cancer and adverse
events that required discontinuation of study or study treatment.
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parable with that observed in other trials using the EVL-CsA
combination (2–4).
The mean levels of systolic and diastolic blood pressure
were within the normal range at 6 and 12 months, although
most patients had to take antihypertensive drugs. It is possible
that the low doses of CsA and steroids used in this trial fa-
vored a better control of blood pressure.
The overall incidence of lymphocele was lower than 20%,
an incidence that is comparable with that observed in transplant
patients not given mammalian target of rapamycin inhibitors
(14, 23) and with the 7.2% to 18.6% reported in former EVL
trials (2, 4, 5, 24, 25). There was a trend for more frequent and
more serious lymphocele in group B.
A limitation of this study is represented by the partial
overlapping of CsA blood levels in the two groups. Most par-
ticipants used doses of CsA higher than scheduled in group B,
so that the differences in blood CsA C2 levels, although sta-
tistically significant, were lower than expected. This issue is
frequent in studies with targeted blood levels of drugs, as
recently reported in a large multicenter RCT (19). The over-
lapping of CsA blood levels between the two groups possibly
contributed to the lack of significance in the difference of
CrCl between groups, the primary outcome measure.
Despite CsA blood levels in group B were not lowered
as expected, the mean C2 blood levels at 12 months in this
group are the lowest levels of CsA obtained in a large, RCT. In
this group, EVL blood levels were within the target ranges up
to month 6, although close to the lower limit, and then
showed a decreasing trend up to the twelfth month. We ob-
served a more frequent EVL discontinuation in group B after
the sixth month. Our data seem to suggest that EVL blood
levels should be reduced after the sixth month, although the
higher than planned CsA blood levels might have contributed
to the higher discontinuation rate after the sixth month.
In summary, this multicenter RCT conducted in a large
number of centers in Italy under standard clinical settings
failed to show that higher EVL blood levels in combination
with very low exposure to CsA further improve CrCl 6
months after kidney transplantation; however, the combina-
tion of upper level EVL with very low-exposure to CsA
showed a significantly better 1-year graft survival, low rate of
BPAR, a good control of CNI related AEs, such as hyperten-
sion, diabetes, gum hyperplasia and hypertrichosis, and a low
rate of serious infections.
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